Ert Pompe denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Pompe Disease ERT as Not FDA-Approved — and How to Correct This Denial

A "not FDA-approved" denial for enzyme replacement therapy for Pompe disease is almost always the result of a mismatch between how the claim was coded, how the prior authorization was submitted, or which specific product was requested versus what Humana's system recognizes. ERT for Pompe disease has FDA-approved products for this indication. If Humana has issued this denial, the most likely explanations are: (1) the specific product's NDC or J-code was entered incorrectly; (2) the stated diagnosis code does not match the FDA-approved indication on file; or (3) Humana's system is treating an off-label scenario that does not apply to your patient.

Once the documentation establishes the correct product, the correct diagnosis, and the FDA approval for that combination, this denial should be reversed without requiring a full-length clinical appeal.

## Federal Appeal Rights

ACA Section 2719 and ERISA Section 503 apply to this denial as they would to any adverse benefit determination. External review is specifically available for experimental or investigational denials under ACA, and a "not FDA-approved" classification is closely related. The external review window is generally four months from the final internal adverse determination. Expedited review is available when delay would seriously jeopardize health.

## What to Gather

• FDA product label — the prescribing information for the specific ERT product, showing the approved indication that matches the patient's diagnosis.
• Correct coding documentation — the J-code or NDC for the product, and the ICD-10 diagnosis code for Pompe disease; confirm with the prescriber's billing team that these are consistent with FDA approval.
• Humana's prior-authorization submission — review the PA request for any coding error, missing indication, or product name mismatch.
• Prescriber letter — a brief letter from the physician confirming the patient's Pompe diagnosis, the specific product requested, and its FDA-approved status for this indication.
• Humana's coverage policy for the product — obtain the current policy to confirm Humana does recognize the product for this indication when properly submitted.

## Criteria-Mapping Structure

This appeal is primarily documentary rather than clinical. Create a checklist: the FDA-approved product name, its approved indication, the matching diagnosis code, and the J-code or NDC — each paired with the source document confirming it. If a coding error caused the denial, document the correction explicitly and request that Humana reprocess.

## Process and Timeline

1. Before filing a formal appeal, call Humana's PA line and confirm whether a coding correction would resolve the denial without a full appeal cycle. 2. If a formal appeal is required, file within the plan's deadline with the FDA label, corrected coding, and prescriber letter. 3. If denied internally, file for external review within four months. 4. Given the typically administrative nature of this denial, resolution at the internal level is common when the correct documentation is submitted.